GRAL

GRAIL, Inc. Common Stock
GRAL

$14.07

0.12%

Market Cap: $437M

About: GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages.

Healthcare Medical Laboratories

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

69.49% more ownership

Funds ownership: 0% [Q1] → 69.49% (+69.49%) [Q2]

30% less call options, than puts

Call options by funds: $1.68M | Put options by funds: $2.39M

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for GRAL.

See Analyst Rankings

Financial journalist opinion

Based on 6 articles about GRAL published over the past 30 days

GRAIL's Potential Turnaround: Seeking FDA Approval For Galleri

Grail's Galleri test detects over 50 cancer types early, potentially saving lives, and is progressing towards FDA approval and broader insurance coverage. The company, a spinoff from Illumina, has significant backing and aims to reduce costs while expanding its market presence and regulatory validation. Despite high cash burn, Grail's strong cash reserves and strategic focus on FDA approval and Medicare reimbursement present substantial upside potential.

GRAIL's Potential Turnaround: Seeking FDA Approval For Galleri

EU top court backs Illumina fight against EU probe into Grail deal

Europe's top court on Tuesday backed U.S. gene sequencing company Illumina's fight against EU antitrust regulators' investigation into its $7.1 billion bid for cancer diagnostic test maker Grail.

EU top court backs Illumina fight against EU probe into Grail deal

GRAIL ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(c)(4)

MENLO PARK, Calif. , Aug. 30, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 182,223 shares of GRAIL's common stock to 55 recently hired non-executive employees as an inducement material to their acceptance of employment with GRAIL.

GRAIL ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(c)(4)

24/7 Wall Street

2 Spinoff Stocks Down 16%. Should You Buy Now?

Stock spinoffs are a popular corporate strategy for unlocking shareholder value, but one that rarely pays off for investors.

2 Spinoff Stocks Down 16%. Should You Buy Now?

Results of GRAIL's Galleri® Multi-Cancer Early Detection Blood Test in Prostate Cancer Published in JCO Precision Oncology

Data Support Clinical Performance of Galleri to Detect More Aggressive Prostate Cancers MENLO PARK, Calif. , Aug. 29, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL) a healthcare company whose mission is to detect cancer early when it can be cured, today announced that detailed findings of the performance of its Galleri® multi-cancer early detection (MCED) test in prostate cancer were published in JCO Precision Oncology.

Results of GRAIL's Galleri® Multi-Cancer Early Detection Blood Test in Prostate Cancer Published in JCO Precision Oncology

GRAIL to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

MENLO PARK, Calif. , Aug. 21, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Morgan Stanley 22nd Annual Global Healthcare Conference at 3:20 p.m.

GRAIL to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

GRAIL Inc. (GRAL) Q2 2024 Earnings Call Transcript

GRAIL Inc. (NASDAQ:GRAL ) Q2 2024 Results Conference Call August 13, 2024 4:30 PM ET Company Participants Bob Ragusa - CEO & Director Aaron Freidin - Chief Financial Officer Joshua Ofman - President Conference Call Participants Tejas Savant - Morgan Stanley Sung Ji Nam - Scotiabank Operator Good day, ladies and gentlemen, and welcome to the GRAIL Second Quarter 2024 Earnings Call. At this time, all participants are in listen-only mode.

GRAIL Inc. (GRAL) Q2 2024 Earnings Call Transcript

Grail to cut jobs, planned hires for 2024 by about 30%

Cancer test maker Grail said on Tuesday it would reduce existing headcount and planned hires for 2024 by about 30%, as part of its restructuring program.

Grail to cut jobs, planned hires for 2024 by about 30%

GRAIL Reports Second Quarter 2024 Financial Results and Provides a Strategic Update

Second Quarter Revenue Grew 43% Year-Over-Year to $32.0 Million Portfolio Prioritization and Corporate Restructure Extends Cash Runway into 2028 MENLO PARK, Calif. , Aug. 13, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the second quarter 2024.

GRAIL Reports Second Quarter 2024 Financial Results and Provides a Strategic Update

GRAIL to Announce Second Quarter 2024 Financial Results

MENLO PARK, Calif. , July 31, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the second quarter 2024 following the close of market on Tuesday, Aug. 13, 2024.

GRAIL to Announce Second Quarter 2024 Financial Results

See News Rankings